1. Pink Sheet
  2. >>Product Reviews

Third Time Lucky for Roche’s Polivy in Europe?

 
• By Maureen Kenny

It’s decision time again at the European Medicines Agency and Roche’s Polivy is one of the new drug applications that is up for a potential marketing recommendation.

Archery_Target
Will Roche hit the target this time round? • Source: Shutterstock

 Editor's note: This article was updated on 15 November 2019 to reflect that the MAA for Polivy did not in fact reach the stage at the July meeting of the CHMP of being up for an opinion on whether it should be recommended for marketing in the EU. 

The European Medicines Agency’s drug evaluation committee, the CHMP, will this week consider again whether polatuzumab vedotin, Roche/Genentech’s new orphan...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

Beijing City Releases AI Action Plan Including Drug Regulation

 
• By Xu Hu

Amid the wait for an action plan to apply AI tools to drug regulation at the national level in China, capital city Beijing has released its own vision of scenarios for the technology in the healthcare sector.

Senate Bill Would Boost Oversight Of US FDA User Fee Program Following Trump Reorganization

 
• By Sarah Karlin-Smith

Senate appropriators also put FDA on notice regarding recent meetings and compliance with the Federal Advisory Committees Act, signal positive news on rare pediatric diseases, and offer hints of other agency areas they have close eyes on.

Slowdown: US FDA’s 2025 Novel Approvals Are On Below-Average Pace

 
• By Bridget Silverman

US FDA's 25 novel approvals in 2025 fell short of the agency's five-year average count, driven by a drop in drugs center approvals; 45 user fee goals remain in second half of year.